Shares of Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is GBX 2,068.75 ($25.55).
A number of equities analysts recently commented on HIK shares. Berenberg Bank lifted their price target on shares of Hikma Pharmaceuticals from GBX 1,960 ($24.21) to GBX 2,000 ($24.70) and gave the stock a “hold” rating in a research note on Monday, February 26th. Barclays reaffirmed an “equal weight” rating and set a GBX 2,000 ($24.70) price target on shares of Hikma Pharmaceuticals in a research note on Monday, April 8th.
View Our Latest Stock Analysis on HIK
Hikma Pharmaceuticals Stock Performance
Hikma Pharmaceuticals Increases Dividend
The firm also recently declared a dividend, which will be paid on Friday, May 3rd. Stockholders of record on Thursday, March 21st will be given a $0.47 dividend. This represents a dividend yield of 1.86%. The ex-dividend date of this dividend is Thursday, March 21st. This is a boost from Hikma Pharmaceuticals’s previous dividend of $0.25. Hikma Pharmaceuticals’s dividend payout ratio is presently 8,507.46%.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Featured Articles
- Five stocks we like better than Hikma Pharmaceuticals
- Pros And Cons Of Monthly Dividend Stocks
- Charles Schwab Fortifies its Uptrend on EPS Beat
- The Most Important Warren Buffett Stock for Investors: His Own
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Stock Dividend Cuts Happen Are You Ready?
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.